Publication Date | SPC No. | SPC Category | Details Rows may repeat to show multiple inventors or applicants depending on "Sort By" |
---|
08 July 2020
(Journal 6842)
| SPC/GB14/069 | Granted | Applicant: Otsuka Pharmaceutical Co., Ltd 9 Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo, 101-8535, Japan
Product: Delamanid optionally in the form of a pharmaceutically acceptable salt
Product Type: Medicinal Authorised: UK EU/1/13/875/001-004 30 April 2014
Authorised Extension:
Patent No: EP1555267 Title: 2,3-DIHYDRO-6-NITROIMIDAZO[2, 1-b]OXAZOLES
SPC No: SPC/GB14/069 Date Granted: 12 June 2020 Maximum Period Expires On: 9 October 2028 |
08 July 2020
(Journal 6842)
| SPC/GB15/017 | Granted | Applicant: Nissan Chemical Industries, Ltd. 7-1, Kanda Nishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054, Japan
Product: Fluralaner or a salt thereof
Product Type: Medicinal Authorised: UK EU/2/13/158/001-015 13 February 2014
Authorised Extension:
Patent No: EP1731512 Title: Isoxazoline-substituted benzamide compound and noxious organism control agent
SPC No: SPC/GB15/017 Date Granted: 12 June 2020 Maximum Period Expires On: 12 February 2029 |
08 July 2020
(Journal 6842)
| SPC/GB15/023 | Granted | Applicant: PTC Therepeutics, Inc. 100 Corporate Court, Middlesex Business Centre, South Plainfield, NJ 07080., USA
Product: 3-[5-(2-Fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (i.e. Ataluren)
Product Type: Medicinal Authorised: UK EU/1/13/902/001 5 August 2014
Authorised Extension:
Patent No: EP1618098 Title: 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
SPC No: SPC/GB15/023 Date Granted: 12 June 2020 Maximum Period Expires On: 8 April 2029 |
08 July 2020
(Journal 6842)
| SPC/GB18/019 | Entered Into Force | Applicant: Kyowa Kirin Co., Ltd. 1-9-2 Otemachi, Tokyo 100-0004, Japan
Product: Benralizumab, an afucosylated antibody that binds to interleukin-5 receptor alpha
Product Type: Medicinal Authorised: UK EU/1/17/1252 10 January 2018
Authorised Extension:
Patent No: EP2270149 Title: Method for controlling the activity of immunologically functional molecule
SPC No: SPC/GB18/019 Date entered into force: 10 June 2020 Effective Period Expires On: 6 April 2025 |
08 July 2020
(Journal 6842)
| SPC/GB20/023 | Lodged | Applicant: Novartis AG Lichstrasse 35, 4056 Basel, Switzerland
Product: glycopyrronium or a salt thereof, especially the bromide salt, and indacaterol maleate, in combination
Product Type: Medicinal Authorised: UK EU/1/13/862 23 September 2013
Authorised Extension:
Patent No: EP2228064 Title: Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
SPC No: SPC/GB20/023 Date Lodged: 9 June 2020 |
08 July 2020
(Journal 6842)
| SPC/GB20/024 | Lodged | Applicant: Gilead Sciences, Inc 333 Lakeside Drive, Foster City, California 94404, USA
Product: Cobicistat or a pharmaceutically acceptable salt or solvate thereof, darunavir or a pharmaceutically acceptable salt or solvate thereof, in particular darunavir ethanolate, and emtricitabine or a pharmaceutically acceptable salt or solvate thereof.
Product Type: Medicinal Authorised: UK EU/1/17/1225 25 September 2017
Authorised Extension:
Patent No: EP3150586 Title: Modulators of pharmacokinetic properties of therapeutics
SPC No: SPC/GB20/024 Date Lodged: 9 June 2020 |
08 July 2020
(Journal 6842)
| SPC/GB20/025 | Lodged | Applicant: Anacor Pharmaceuticals, Inc. 235 East 42nd Street, New York,, NY, 10017, USA
Product: crisaborole, optionally in the form of a pharmaceutically acceptable salt
Product Type: Medicinal Authorised: UK EU/1/19/1421 1 April 2020
Authorised Extension:
Patent No: EP2343304 Title: Biocidal boronophthalide compounds
SPC No: SPC/GB20/025 Date Lodged: 1 June 2020 |